Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
164 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Anxiety Disorders - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H2 2014', provides an overview of the Anxiety Disorders's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anxiety Disorders Overview 8 Therapeutics Development 9 Pipeline Products for Anxiety Disorders - Overview 9 Pipeline Products for Anxiety Disorders - Comparative Analysis 10 Anxiety Disorders - Therapeutics under Development by Companies 11 Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 15 Anxiety Disorders - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Anxiety Disorders - Products under Development by Companies 19 Anxiety Disorders - Products under Investigation by Universities/Institutes 22 Anxiety Disorders - Companies Involved in Therapeutics Development 23 Ache Laboratorios Farmaceuticos S/A 23 Adamed Sp. z o.o. 24 Addex Therapeutics Ltd 25 Avineuro Pharmaceuticals, Inc. 26 Azevan Pharmaceuticals, Inc. 27 Beech Tree Labs, Inc. 28 Bionomics Limited 29 Boehringer Ingelheim GmbH 30 C4X Discovery Ltd 31 Concert Pharmaceuticals, Inc. 32 Eisai Co., Ltd. 33 Eli Lilly and Company 34 F. Hoffmann-La Roche Ltd. 35 GW Pharmaceuticals plc 36 HolsboerMaschmeyer NeuroChemie GmbH 37 Johnson & Johnson 38 Merz Pharmaceuticals GmbH 39 MI.TO. Technology S.r.L. 40 Newron Pharmaceuticals S.p.A. 41 Nuvo Research Inc. 42 Omeros Corporation 43 Richter Gedeon Nyrt. 44 Rottapharm SpA 45 Sigma-Tau S.p.A. 46 SK Biopharmaceuticals Co., Ltd. 47 Suda Ltd 48 Sumitomo Dainippon Pharma Co., Ltd. 49 Trevena, Inc. 50 Anxiety Disorders - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 55 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 ADN-2013 - Drug Profile 62 ADX-71441 - Drug Profile 63 ADX-88178 - Drug Profile 64 alprazolam - Drug Profile 65 AVL-5189 - Drug Profile 66 AVN-101 - Drug Profile 67 AVN-397 - Drug Profile 68 AVN-628 - Drug Profile 69 AZ-01 - Drug Profile 70 BCA-909 - Drug Profile 71 BNC-210 - Drug Profile 73 BTL-ng - Drug Profile 75 CR-5542 Series - Drug Profile 76 CTP-354 - Drug Profile 77 dipraglurant IR - Drug Profile 78 Drugs to Activate HAT for CNS Disorders - Drug Profile 79 Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 80 Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 81 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 82 E-2508 - Drug Profile 83 itriglumide - Drug Profile 84 JNJ-31020028 - Drug Profile 85 JNJ-42165279 - Drug Profile 86 LSN-2535717 - Drug Profile 87 LY-2607540 - Drug Profile 88 midazolam hydrochloride - Drug Profile 89 MRZ-8676 - Drug Profile 91 nabiximols - Drug Profile 92 NB-51R1 - Drug Profile 95 NW-3509 - Drug Profile 96 Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 97 Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - Drug Profile 98 PT-00114 - Drug Profile 99 PT-00121 - Drug Profile 100 PT-00211 - Drug Profile 101 PT-00411 - Drug Profile 102 RGH-618 - Drug Profile 103 Ro-646198 - Drug Profile 105 SCT-66 - Drug Profile 106 Small Molecule to Agonize mGluR2 for Anxiety Disorders - Drug Profile 107 Small Molecule to Antagonize Corticotropin-Releasing Factor 1 Receptor for Anxiety Disorders - Drug Profile 108 Small Molecule To Antagonize GPR31 for Anxiety Disorders - Drug Profile 109 Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 110 Small Molecules for Depression and Anxiety - Drug Profile 111 Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 112 Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 113 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 114 Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 115 Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders - Drug Profile 116 Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 117 Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 118 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 119 Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile 120 Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 121 Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 122 ST-4070 - Drug Profile 123 Synthetic Peptide for Anxiety Disorders - Drug Profile 124 TPI-136117 - Drug Profile 125 VAD-1 - Drug Profile 126 VAD-2 - Drug Profile 127 YKP-3089 - Drug Profile 128 Anxiety Disorders - Recent Pipeline Updates 130 Anxiety Disorders - Dormant Projects 144 Anxiety Disorders - Discontinued Products 147 Anxiety Disorders - Product Development Milestones 150 Featured News & Press Releases 150 Appendix 158 Methodology 158 Coverage 158 Secondary Research 158 Primary Research 158 Expert Panel Validation 158 Contact Us 159 Disclaimer 159
List of Tables Number of Products under Development for Anxiety Disorders, H2 2014 14 Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Comparative Analysis by Unknown Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Development by Companies, H2 2014 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2014 27 Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 28 Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2014 29 Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2014 30 Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2014 31 Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 32 Anxiety Disorders - Pipeline by Beech Tree Labs, Inc., H2 2014 33 Anxiety Disorders - Pipeline by Bionomics Limited, H2 2014 34 Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2014 35 Anxiety Disorders - Pipeline by C4X Discovery Ltd, H2 2014 36 Anxiety Disorders - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 37 Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2014 38 Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2014 39 Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 40 Anxiety Disorders - Pipeline by GW Pharmaceuticals plc, H2 2014 41 Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2014 42 Anxiety Disorders - Pipeline by Johnson & Johnson, H2 2014 43 Anxiety Disorders - Pipeline by Merz Pharmaceuticals GmbH, H2 2014 44 Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H2 2014 45 Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 46 Anxiety Disorders - Pipeline by Nuvo Research Inc., H2 2014 47 Anxiety Disorders - Pipeline by Omeros Corporation, H2 2014 48 Anxiety Disorders - Pipeline by Richter Gedeon Nyrt., H2 2014 49 Anxiety Disorders - Pipeline by Rottapharm SpA, H2 2014 50 Anxiety Disorders - Pipeline by Sigma-Tau S.p.A., H2 2014 51 Anxiety Disorders - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 52 Anxiety Disorders - Pipeline by Suda Ltd, H2 2014 53 Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 54 Anxiety Disorders - Pipeline by Trevena, Inc., H2 2014 55 Assessment by Monotherapy Products, H2 2014 56 Number of Products by Stage and Target, H2 2014 58 Number of Products by Stage and Mechanism of Action, H2 2014 61 Number of Products by Stage and Route of Administration, H2 2014 64 Number of Products by Stage and Molecule Type, H2 2014 66 Anxiety Disorders Therapeutics - Recent Pipeline Updates, H2 2014 135 Anxiety Disorders - Dormant Projects, H2 2014 149 Anxiety Disorders - Discontinued Products, H2 2014 152 Anxiety Disorders - Discontinued Products (Contd..1), H2 2014 153 Anxiety Disorders - Discontinued Products (Contd..2), H2 2014 154
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.